Arg440

Site Information
NGDFGrGrRTLFRGR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 8093789

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 )
Disease tissue studied:	testicular cancer ( 3 )
Relevant cell line - cell type - tissue:	'brain, embryonic' ( 7 ) , F9 (testicular) ( 3 ) , kidney ( 4 ) , lung ( 5 ) , MEF (fibroblast) ( 6 ) , PYS-2 (epithelial) ( 2 )

References
1	Zhou J (2010) CST Curation Set: 9110; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
2	Zhou J (2010) CST Curation Set: 9115; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
3	Zhou J (2010) CST Curation Set: 9111; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
4	Zhou J (2009) CST Curation Set: 7948; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
5	Zhou J (2009) CST Curation Set: 7946; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
6	Zhou J (2009) CST Curation Set: 6011; Year: 2012; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
7	Zhou J (2008) CST Curation Set: 3812; Year: 2008; Biosample/Treatment: tissue, brain, embryonic/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info